ciprofloxacin has been researched along with quinoxalines in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nasr, MN | 1 |
| Cho, JH; Jeong, SH; Song, YK | 1 |
| Bonomo, RA; Chen, L; Coakley, P; Hujer, AM; Kreiswirth, BN; Marshall, SH; Paterson, DL; Perez, F; Rather, PN; Rudin, SD; Toltzis, P; van Duin, D | 1 |
| Basak, M; Bhattacharjee, B; Das, G; Ramesh, A | 1 |
4 other study(ies) available for ciprofloxacin and quinoxalines
| Article | Year |
|---|---|
Synthesis and antibacterial activity of fused 1, 2, 4-triazolo[4, 3-a]quinoxaline and oxopyrimido[2', 1':5, 1]-1, 2, 4-triazolo[4, 3-a]quinoxaline derivatives.
Topics: Anti-Bacterial Agents; Bacteria; Chemical Phenomena; Chemistry, Physical; Ciprofloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Indicators and Reagents; Microbial Sensitivity Tests; Pyrimidines; Quinoxalines; Triazoles | 2002 |
Risk assessment of ciprofloxacin, flavomycin, olaquindox and colistin sulfate based on microbiological impact on human gut biota.
Topics: Adult; Bacteria, Aerobic; Bacteria, Anaerobic; Bambermycins; Ciprofloxacin; Colistin; Feces; Female; Humans; Intestines; Microbial Sensitivity Tests; No-Observed-Adverse-Effect Level; Quinoxalines; Risk Assessment; Veterinary Drugs; Young Adult | 2009 |
OqxAB, a quinolone and olaquindox efflux pump, is widely distributed among multidrug-resistant Klebsiella pneumoniae isolates of human origin.
Topics: Americas; Animals; Anti-Bacterial Agents; Asia; Australia; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Genes, MDR; Humans; Klebsiella Infections; Klebsiella pneumoniae; Quinolones; Quinoxalines; Swine; Swine Diseases | 2013 |
Quinoxaline-based membrane-targeting therapeutic material: Implications in rejuvenating antibiotic and curb MRSA invasion in an in vitro bone cell infection model.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Ligands; Methicillin-Resistant Staphylococcus aureus; Quinoxalines; Staphylococcus aureus | 2023 |